natgillin/translations-raw huggingface dataset:
The mobile communication system of claim 1, wherein the amount of resources for the ACK or the NACK does not exceed a predefined amount. The mobile communication system of claim 1, before transmitting the ACK or the NACK to the base station apparatus (100), the mobile station apparatus (200) further maps ACK or NACK modulation symbols onto a part of symbols in the time domain of the uplink resources, wherein the number of the mapped ACK or NACK modulation symbols is equal to or less than the calculated amount of resources, and does not exceed a predefined amount. 
Sustav mobilne komunikacije prema zahtjevu 1, naznačen time da se količina resursa za ACK ili NACK koji se istovremeno odašilju sa odlaznim podacima izračunava tako da količina resursa ne prelazi prethodno određenu količinu. Sustav mobilne komunikacije prema zahtjevu 1. naznačen time da se količina resursa za ACK ili NACK koji se istovremeno odašilju sa odlaznim podacima izračunava tako da količina resursa ne padne ispod prethodno određene količine. Sustav mobilne komunikacije prema zahtjevu 2 ili 3, naznačen time da je prethodno određena količina postavljena od strane radio signala kontrole resursa koji odašilje uređaj bazne stanice (100).
the amount of resources for the ACK or the NACK is calculated based on the resource allocation information. The mobile station apparatus (200) of claim 4, wherein the amount of resources for the ACK or the NACK does not exceed a predefined amount. 
Uređaj mobilne stanice (200) prema zahtjevu 5, naznačen time da se količina resursa za ACK ili NACK koji se istovremeno odašilju sa odlaznim podacima izračunava tako da količina resursa ne prelazi prethodno određenu količinu.
the amount of resources for the ACK and NACK is calculated based on the resource allocation information. The base station apparatus (100) of claim 7, wherein the amount of resources for the ACK or the NACK does not exceed a predetermined amount. 
Uređaj bazne stanice (100) prema zahtjevu 8, naznačen time da se količina resursa za ACK ili NACK koji se istovremeno odašilju sa odlaznim podacima izračunava tako da količina resursa ne prelazi unaprijed određenu količinu.
The compound according to claim 1 selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time, da je odabran iz sljedeće skupine:
A pharmaceutical composition comprising a compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od prethodnih zahtjeva ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljiv nosač ili prihvatljivo pomoćno sredstvo.
The use of a compound according to claim 1 in the manufacture of a medicament for the treatment of cancer. 
Uporaba spoja prema zahtjevu 1, naznačena time, da je za proizvodnju lijeka za liječenje raka.
a first inner layer (11, 111, 211, 411), to be directed toward the body of the user, which is substantially hydrophobic and breathable and is suitable to direct liquid-phase and vapor-phase perspiration away from the user of an item of clothing or the like produced with said fabric (10), 
prvog unutarnjeg sloja (11, 111, 211, 411) koji je okrenut prema tijelu korisnika, koji je u biti hidrofoban i prozračan i koji je pogodan za izravno isparavanje tekućeg i parovitog znoja od korisnika odjevnog predmeta ili slično, proizvedenog uz pomoć navedene tkanine (10),
a second intermediate spacing layer (12, 112, 212, 412), which is substantially hydrophobic and transfers the liquid-phase perspiration from said first inner layer (11, 111, 211, 411) toward a third outer layer (13, 113, 213), 
drugog međusloja za održavanje razmaka (12, 112, 212, 412), koji je u biti hidrofoban i prenosi tekuću fazu znoja iz prvog unutarnjeg sloja (11, 111, 211, 411) prema trećem vanjskom sloju (13, 113, 213),
a third outer layer (13, 113,213) which is substantially hydrophilic and is suitable for permeation of vapor-phase perspiration, for absorbing liquid-phase perspiration that arrives from the first layer (11, 111, 211, 411), and for distributing said liquid-phase perspiration over a large surface thereof so that it can evaporate outwardly, 
trećeg vanjskog sloja (13, 113, 213), koji je u biti hidrofilan i pogodan je za propuštanje znoja u parovitom stanju, za apsorpciju tekuće faze znoja koji dolazi iz prvog sloja (11, 111, 211, 411) i za raspodjelu navedene tekuće faze znoja na velikoj površini tako da se može ispariti prema van,
The fabric according to claim 1, characterized in that said first inner layer (11) is formed by strips of hydrophobic fabric (16, 416), each of which is arranged so as to affect a corresponding rib of said ribs (15, 115, 415). 
Tkanina u skladu s patentnim zahtjevom 1, naznačena time, da se prvi unutarnji sloj (11) sastoji od traka hidrofobne tkanine (16, 416), od kojih je svaka postavljena tako da djeluje na odgovarajuće rebro navedenih rebara (15, 115, 415).
The fabric according to one or more of the preceding claims, characterized in that said first layer (11) is made of hydrophobic fibers of polyester or polypropylene or other equivalent hydrophobic fibers. 
Tkanina u skladu s jednim ili više prethodnih patentnih zahtjeva, naznačena time, da je navedeni prvi sloj (11) izrađen od hidrofobnih vlakana poliestera ili polipropilena ili drugih ekvivalentnih hidrofobnih vlakana.
The fabric according to one or more of the preceding claims, characterized in that said second intermediate layer (12) is made of hydrophobic fibers of polyester or polypropylene or other equivalent hydrophobic fibers. 
Tkanina u skladu s jednim ili više prethodnih patentnih zahtjeva, naznačena time, da se navedeni drugi međusloj (12) sastoji od hidrofobnih vlakana poliestera ili polipropilena ili drugih ekvivalentnih hidrofobnih vlakana.
The fabric according to one or more of the preceding claims, characterized in that said ribs (15) of the second layer (12), joined to the corresponding strips (16) of the first layer (11), have a thickness of no less than 2 millimeters and preferably in the range from 3 to 4 millimeters. 
Tkanina u skladu s jednim ili više prethodnih patentnih zahtjeva, naznačena time, da navedena rebra (15) drugog sloja (12), spojena na odgovarajuće trake (16) prvog sloja (11), imaju debljinu od najmanje 2 mm a poželjno u rasponu od 3 do 4 milimetra.
The fabric according to one or more of the preceding claims, characterized in that said strips of fabric (16) of the first layer (11) have a width of no less than 2 millimeters and no more than 6 millimeters, preferably a width of approximately 4 millimeters. 
Tkanina u skladu s jednim ili više prethodnih patentnih zahtjeva, naznačena time, da navedene trake tkanine (16) prvog sloja (11) imaju širinu od najmanje 2 mm i ne više od 6 mm, poželjno širinu od oko 4 mm.
The fabric according to claims 1, 3, 4 and 8, characterized in that said first inner breathable layer (111) is constituted by a finely perforated continuous fabric. 
Tkanina u skladu s patentnim zahtjevima 1, 3, 4 i 8, naznačena time, da se navedeni prozračni prvi unutarnji sloj (111) sastoji od fino perforirane kontinuirane tkanine.
The fabric according to claims 1, 3, 4 and 8, characterized in that said first inner breathable layer (211) is constituted by a diffusely macroperforated fabric. 
Tkanina u skladu s patentnim zahtjevima 1, 3, 4 i 8, naznačena time, da se navedeni prvi unutarnji prozračni sloj (211) sastoji od difuzno makroperforirane tkanine.
The fabric according to claims 10 and 11, characterized in that said holes (217, 317) and the corresponding openings (218, 318) in the second layer (212) form said preferential passages for the vapor from said first layer (211) outwardly. 
Tkanina u skladu s patentnim zahtjevima 10 i 11, naznačena time, da rupe (217, 317) i odgovarajući otvori (218, 318) u drugom sloju (212) tvore navedene preferencijalne prolaze za paru iz navedenog prvog sloja (211) prema van.
The fabric according to claim 15, characterized in that said fourth layer comprises a waterproof breathable membrane. 
Tkanina u skladu s patentnim zahtjevom 15, naznačena time, da navedeni četvrti sloj sadržava vodootpornu membranu propusnu za zrak.
The lithium accumulator of any of the preceding claims 1 to 3 wherein distribution pipes (14) are located within passages (34) and the ends of the distribution pipes (14) are connected to a distribution system of the heat exchange medium. 
Litijev akumulator sukladno bilo kojem od prethodnih zahtjeva 1 do 3, u kome se cijevi za distribuciju (14) nalaze unutar prolaza (34) a krajevi cijevi za distribuciju (14) spojeni su na distribucijski sustav toplinski promjenjivog medija.
The lithium accumulator of claim 4 wherein the heat exchange medium distribution system includes a pump (8) and a heat exchanger (18). 
Litijev akumulator sukladno zahtjevu 4, u kome sustav za distribuciju toplinski promjenjivog medija uključuje pumpu (8) i izmjenjivač topline (18).
The lithium accumulator of any of the preceding claims 1 to 3 wherein the heat exchange medium is electrolyte. 
Litijev akumulator sukladno bilo kojem od prethodnih zahtjeva 1 do 3, u kome je toplinski promjenjivi medij elektrolit.
The lithium accumulator of any of the preceding claims 6 to 7 wherein one cover (1c) is connected to an inlet piping (81) of the electrolyte distribution system and the other cover (1d) is connected to a return piping (82) of the electrolyte distribution system. 
Litijev akumulator sukladno bilo kojem od prethodnih zahtjeva 6 do 7, u kome je jedan poklopac (1c) spojen na ulazni vod (81) distribucijskog sustav elektrolita a drugi poklopac (1d) povezan je na povratni vod (82) distribucijskog sustava elektrolita.
The lithium accumulator of claim 9 wherein the electrolyte distribution system includes a pump (8) and a heat exchanger (18). 
Litijev akumulator sukladno zahtjevu 9, u kome sustav za distribuciju elektrolita uključuje pumpu (8) i izmjenjivač topline (18).
The lithium accumulator of claim 10 wherein an electrolyte regeneration unit (19) is incorporated into the return piping (82). 
Litijev akumulator sukladno zahtjevu 10, u kome je jedinica za obnavljanje elektrolita (19) ugrađena u povratni vod (82).
The lithium accumulator of claim 12 wherein the electrically conductive foils (51, 53) are perforated (56). 
Litijev akumulator sukladno zahtjevu 12 u kome su električno vodljive folije (51, 53) perforirane (56).
The lithium accumulator of any of the preceding claims 1 to 14 wherein the electro-insulating material (55) is a plasma coated porous electro-insulating material. 
Litijev akumulator sukladno bilo kojem od prethodnih zahtjeva 1 do 14, u kome je elektro-izolacijski materijal (55) porozan elektro-izolacijski materijal obložen plazmom.
The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein ring A is either one of the rings of the following formula (5): X is -CH2O- or -(CH2)2-, R2 is a phenyl group or a pyridyl group (said phenyl group or pyridyl group may be substituted by 1-3 methoxy groups.) 
Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time da je prsten A bilo koji od prstenova sa slijedećim formulama (5): [image] X je -CH2O- ili -(CH2)2-, je fenil skupina ili piridil skupina (navedena fenil skupina ili piridil skupina mogu biti supstituirane s 1-3 metoksi skupine).
The mobile station apparatus (200) of claim 5, wherein the mobile station apparatus (200) further comprises means for receiving a RRC signaling including information indicating the maximum amount of resources in which the ACK or NACK can be mapped. 
Uređaj mobilne stanice (200) prema zahtjevu 5, naznačen time da se količina resursa za ACK ili NACK koji se istovremeno odašilju sa odlaznim podacima izračunava tako da količina resursa ne padne ispod prethodno određene količine.
The communication method of claim 11, further comprising: receiving a RRC signaling including information indicating the maximum amount of resources in which the ACK or NACK can be mapped. 
Komunikacijski postupak prema zahtjevu 11, da se količina resursa za ACK ili NACK koji se istovremeno odašilju sa odlaznim podacima izračunava tako da količina resursa ne padne ispod prethodno određene količine.
A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to any one of claims 1 to 13 or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 13, ili njegove farmaceutski podnošljive soli, i farmaceutski podnošljive nosače.
Compounds according to any one of claims 1 to 13 for the preparation of medicaments for the treatment of a metabolic disorder. 
Spojevi prema bilo kojem od zahtjeva 1 do 13, naznačeni time, da se upotrebljavaju u proizvodnji lijekova za liječenje metaboličkog poremećaja.
The use of a compound according to any one of claims 1 to 13 for the preparation of medicaments for the treatment of diabetes, obesity or metabolic syndrome. The invention as hereinbefore described. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 13, naznačena time, da je za proizvodnju lijekova za liječenje dijabetesa, pretilosti i metaboličkog sindroma.
metformin or/and a pharmaceutically acceptable salt thereof, wherein the metformin or/and the pharmaceutically acceptable salt thereof is particularly to be administered orally. 
metformin ili/i njegovu farmaceutski prihvatljivu sol, pri čemu se metformin ili/i njegova farmaceutski prihvatljiva sol naročito treba davati oralno.
The pharmaceutical combination for the use of any one of the claims 1 to 7, wherein the sulfonyl urea is suitable for the treatment of diabetes type 2 and is particularly selected from Glibenclamide, Glibenclamide MR, Gliclazide, Gliclazide LM, Glimepiride, Glipizide, Glipizide XL, Gliquidone, and Tolbutamide. 
Farmaceutska kombinacija za upotrebu prema bilo kojem od zahtjeva 1 do 7, naznačena time da je sulfonil urea pogodna za liječenje dijabetesa tipa 2 i naročito je odabrana od Glibenklamid, Glibenklamid MR, Gliklazid, Gliklazid LM, Glimepirid, Glipizid, Glipizid XL, Gliquidon, te Tolbutamid.
desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, particularly for subcutaneous administration, and 
desPro36Exendin-4(1-39)-Lys6-NH2 ili/i njegovu farmaceutski prihvatljivu sol, naročito za potkožnu primjenu, te
a sulfonyl urea or/and a pharmaceutically acceptable salt thereof, particularly for oral administration. 
sulfonil ureu ili/i njegovu farmaceutski prihvatljivu sol, naročito za oralnu primjenu.
metformin or/and a pharmaceutically acceptable salt thereof, particularly for oral administration. 
metformin ili/i njegovu farmaceutski prihvatljivu sol, naročito za oralnu primjenu.
A composition as claimed in claim 20 in a dosage form suitable for transdermal administration. 
Smjesa prema zahtjevu 20, naznačena time, što je u doznoj formi pogodnoj za transdermalnu primjenu.
Use of a compound as claimed in any one of claims 15 to 19 in the manufacture of a medicament for the treatment of pain. 
Uporaba spoja prema bilo kojem od zahtjeva 15 do 19, naznačena time, što se spoj uporabljuje za izradu medikamenta za liječenje boli.
when X represents a direct bond, then R2 does not represent halo; 
kada X predstavlja izravnu vezu, tada R2 ne predstavlja halo;
Z and M represents direct bonds, R3 represents -CH3, then: 
Z i M predstavljaju izravne veze, R3 predstavlja -CH3, tada:
Z and M represent direct bonds, R1 represents -CH3, R3 represents hydrogen, then R2 does not represent unsubstituted phenyl when X represents a direct bond; 
Z i M predstavljaju izravne veze, R1 predstavlja -CH3, R3 predstavlja vodik, tada R2 ne predstavlja nesupstituirani fenil kada X predstavlja izravnu vezu;
Z, M and X represent direct bonds, then: 
Z, M i X predstavljaju izravne veze, tada:
when R1 represents 4-chlorophenyl or unsubstituted phenyl, then R2 does not represent unsubstituted phenyl or 4-chlorophenyl; 
kada R1 predstavlja 4-klorofenil ili nesupstituirani fenil, tada R2 ne predstavlja nesupstituirani fenil ili 4-klorofenil;
when R1 represents 4-methoxyphenyl, then R3 does not represent 4-chlorophenyl or unsubstituted phenyl. 
kada R1 predstavlja 4-metoksifenil, tada R3 ne predstavlja 4-klorofenil ili nesupstituirani fenil.
Z, M and X represent direct bonds, R3 represents H, then: 
Z, M i X predstavljaju izravne veze, R3 predstavlja H, tada:
X and M represent direct bonds, R2 represents methyl, R3 represents ethyl, then: 
X i M predstavljaju izravne veze, R2 predstavlja metil, R3 predstavlja etil, tada:
when Z represents -NHC(O)-, then R1 does not represent unsubstituted methyl; 
kada Z predstavlja -NHC(O)-, tada R1 ne predstavlja nesupstituirani metil;
methylene) and R1 represents unsubstituted phenyl, then: 
metilen) i R1 predstavlja nesupstituirani fenil, tada:
when R3 represents hydrogen, then R2 does not represent -CH3; 
kada R3 predstavlja vodik, tada R2 ne predstavlja -CH3;
for use as a pharmaceutical. 
za uporabu kao lijek.
A compound, as defined in any one of Claims 1 to 5 but without the provisos, or a pharmaceutically acceptable solvate or salt thereof, for use in the treatment of a disease selected from the group consisting of cancer, an inflammatory disease, immunosuppression, benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis, post-surgical stenosis and restenosis, a viral condition, a parasitic condition and a neurodegenerative disorder. 
Spoj, kao što je definirano u bilo kojem od zahtjeva 1 do 5 ali bez uvjeta, ili njegov farmaceutski prihvatljiv solvat ili sol, naznačen time da je za uporabu za liječenje bolesti odabrane iz skupine koju čine rak, upalna bolest, imunosupresivni poremećaj, benigna hiperplazija prostate, obiteljska adenomatoza, polipoza, neurofibromatoza, psorijaza, proliferacija glatkih vaskularnih stanica povezana s aterosklerozom, plućna fibroza, artritis glomerulonefritis, post operativna stenoza i restenoza, virusno stanje, parazitsko stanje i neurodegenerativni poremećaj.
Use of a compound of formula I, as defined in any one of Claims 1 to 5 but without the provisos, or a pharmaceutically acceptable solvate or salt thereof, for the manufacture of a medicament for the treatment of a disease selected from the group consisting of cancer, an inflammatory disease, immunosuppression, benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis, post-surgical stenosis and restenosis, a viral condition, a parasitic condition and a neurodegenerative disorder. 
Uporaba spoja s formulom I, kao što je definirano u bilo kojem od zahtjeva 1 do 5 ali bez uvjeta, ili njegovog farmaceutski prihvatljivog solvata ili soli, naznačena time da je za proizvodnju lijeka za liječenje bolesti odabrane iz skupine koju čine rak, upalna bolest, imunosupresivni poremećaj, benigna hiperplazija prostate, obiteljska adenomatoza, polipoza, neurofibromatoza, psorijaza, proliferacija glatkih vaskularnih stanica povezana s aterosklerozom, plućna fibroza, artritis glomerulonefritis, post operativna stenoza i restenoza, virusno stanje, parazitsko stanje i neurodegenerativni poremećaj.
a pharmaceutical formulation including another therapeutic agent that is useful in the treatment of cancer and/or a proliferative disease in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other. 
farmaceutsku formulaciju koja sadrži drugo terapijsko sredstvo koje je korisno za liječenje raka i/ili proliferativne bolesti u smjesi s farmaceutski prihvatljivim pomoćnim sredstvom, razrjeđivačem ili nosačem, navedene komponente (a) i (b) su svaka predviđene u obliku koji je pogodan za davanje u kombinaciji s drugom.
(xiii) for compounds of formula I in which there is a -CH2- group present, reduction of a corresponding compound of formula I in which there is a -C(OH)- group present; 
(xiii) za spojeve s formulom I u kojoj se nalazi -CH2- skupina, redukciju odgovarajućeg spoja s formulom I u kojoj se nalazi -C(OH)- skupina;
Rb is -NRxRy, wherein Rx and Ry are independently selected from hydrogen, C1-4alkoxy, C1-4alkoxyC1-4alkyl, C1-4alkoxycarbonyl, C1-6alkyl, C3-7cycloalkyl, (C3-7cycloalkyl)C1-4alkyl, hydroxyC1-4alkyl, and trideuteromethyl, wherein the alkyl part of the (C3-7cycloalkyl)C1-4alkyl can be optionally substituted with a C1-4alkoxy group; or, Rx and Ry, together with the nitrogen atom to which they are attached, form a four- to seven-membered monocyclic or bicyclic ring optionally containing one double bond and optionally containing one additional heteroatom selected from O, NRz, and S; wherein Rz is selected from hydrogen, C1-6alkyl, and C1-4alkoxycarbonyl; and wherein the ring is optionally substituted with one or two substituents independently selected from C1-6alkoxy, C1-6alkyl, halo, haloC1-4alkyl, hydroxy,-NRfRg, oxo, spirocyclic dioxolanyl; wherein Rf and Rg are independently selected from hydrogen, C1-4alkoxycarbonyl, and C1-6alkyl; 
Rb je –NRxRy, pri čemu su Rx i Ry nezavisno odabrani između vodika, C1-4alkoksi, C1-4alkoksiC1-4alkila, C1-4alkoksikarbonila, C1-6alkila, C3-7cikloalkila, (C3-7cikloalkil)C1-4alkila, hidroksiC1-4alkila i trideuterometila, pri čemu alkilni dio (C3-7cikloalkil)C1-4alkila može opcionalno biti supstituiran s C1-4alkoksi grupom; ili Rx i Ry, zajedno s atomom dušika za koji su vezani, tvore četvero- do sedmeročlani monociklički ili biciklički prsten koji opcionalno sadrži jednu dvostruku vezu i opcionalno sadrži jedan dodatni heteroatom odabran između O, NRz i S; pri čemu je Rz odabran između vodika, C1-6alkila i C1-4alkoksikarbonila; i pri čemu je prsten opcionalno supstituiran s jednim ili dva supstituenata nezavisno odabranih između C1-6alkoksi, C1-6alkila, halo, haloC1-4alkila, hidroksi, –NRfRg, okso, spirocikličkog dioksolanila; pri čemu su Rf i Rg nezavisno odabrani između vodika, C1-4alkoksikarbonila i C1-6alkila;
A compound for use according to claim 17 wherein said disorder is selected from Alzheimer's Disease and Down Syndrome. 
Tvar za uporabu u skladu s patentnim zahtjevom 17 pri čemu je navedeni poremećaj odabran između Alzheimerove bolesti i sindroma Down.
A compound for use according to claim 18 wherein said disorder is Alzheimer's Disease. 
Tvar za uporabu u skladu s patentnim zahtjevom 18 pri čemu je navedeni poremećaj Alzheimerova bolest.
in the activated state: 
u aktiviranom stanju:
A process for preparing cortexolone-17a-propionate in crystalline form I, comprising: reacting a compound of Formula IIa: wherein R is CH3CH2, with a compound of Formula III R'OH (III) wherein R' is a linear aliphatic chain containing 1-10 carbon atoms, in the presence of a lipase from Candida, and crystallizing the cortexolone-17a-propionate of crystalline form I from tert-butylmethylether solvent. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što se korteksolon-17a-propionat dobiva reakcijom spoja Formule IIa: [image], gdje je R CH3CH2, sa spojem Formule III R′OH (III) gdje je R′ nerazgranati alifatski lanac s 1-10 atoma ugljika, kako bi se dobilo korteksolon-17a-propionat, u prisutnosti lipaze iz kvasca Candida.
Pharmaceutical or nutritional compositions according to claims 1-2, for use in the prevention and/or treatment of gastroesophageal reflux disease. 
Farmaceutski ili nutritivni sastav prema patentnom zahtjevu 1 za uporabu u prevenciji i/ili liječenju bolesti gastroezofagijalnog refluksa.
A pharmaceutical formulation according to claim 12, characterized in that nifuratel sulfoxide is in form of a single stereoisomer or a mixture of stereoisomers. 
Farmaceutske formulacije u skladu s patentnim zahtjevom 12, naznačene time što je nifuratel-sulfoksid u obliku pojedinačnog stereoizomera ili smjese stereoizomera.